Richter Transformation clinical trials

Explore recruiting richter transformation clinical trials.

Recruiting richter transformation studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Richter Transformation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

Austria, Germany, Denmark, Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, WITH AND WITH-OUT SONROTOCLAX (BGB-11417), A BCL2 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION - CLL-RT1-Trial

Denmark, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)

France, Germany, Spain, Sweden, Italy, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)

Sweden, Germany, Denmark, Poland, Norway, Finland +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

Netherlands, Belgium, Finland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Richter Transformation trials by city

Richter Transformation clinical trials

Recruiting richter transformation studies right now

A Study of NX-1607 in Adults With Advanced Malignancies

ONO-4538 Study in Patients With Richter's Transformation

CD45BE-HSPC + CART-45 Cells

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Also recruiting in Europe

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

Richter Transformation trials by city

Other conditions